Health Condition 1: I824- Acute embolism and thrombosis of deep veins of lower extremity Health Condition 2: null- Venous Thromboembolism
Conditions
Interventions
None listed
Sponsors
Sanofi India Limited
Eligibility
Inclusion criteria
Inclusion criteria: Women with objectively confirmed pregnancy coming for: a) First prenatal consultation or any consultation occurring during pregnancy b) Intercurrent medical condition with or without need for hospitalisation c) Labour/ delivery 3. Women having signed informed consent at enrolment in the study.
Exclusion criteria
Exclusion criteria: 1. Women who have experienced VTE (DVT and/or PE) in the 4 months before inclusion in the trial 2. Women already receiving antithrombotic therapy for medical reason: previous VTE, atrial fibrillation, mechanical prosthetic heart valves 3. Refusal or inability to give informed consent to participate in the study. 4. Current participation in any other clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of women at risk of VTE during pregnancy and post-partum period.Timepoint: Q3 2016 | — |
Secondary
| Measure | Time frame |
|---|---|
| "The proportion of at risk women receiving effective type of VTE Prophylaxis according to ACCP and/or RCOG guidelines. - The factors driving VTE prophylaxis decisions - The overall rate of patients receiving mechanical vs. pharmacological prophylaxis - The proportion of physicians following international guidelines - The association between physicianâ??s knowledge of the guidelines and their attitude regarding VTE Prophylaxis " Timepoint: Q3 2016 | — |
Countries
Azerbaijan, Bangladesh, Egypt, Georgia, Ghana, India, Iraq, Jordan, Kenya, Lebanon, Morocco, Nigeria, Pakistan, Russian Federation, Saudi Arabia, South Africa, Tunisia, United Arab Emirates, Uzbekistan
Contacts
Public ContactMr Ajit Walekar
Sanofi India Limited
Outcome results
None listed